cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/pr00008076
title: Safety and tolerability of the new phosphodiesterase inhibitor (B9302-107) administered to healthy male volunteers as ascending repeated oral doses over 7 days

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008080
title: Anti-inflammatory activity of roflumilast. Study on the efficacy of oral roflumilast (500 \xb5g/d) over 4 weeks on sputum neutrophils in chronic obstructive pulmonary disease (COPD) patients. A double-blind, randomized, placebo-controlled, 2-period, cross-over study\n

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008081
title: Anti-inflammatory activity of roflumilast: Study on the efficacy of oral roflumilast (500 \xb5g/d) over 4 weeks on sputum eosinophils in patients with asthma. A double-blind randomized placebo-controlled parallel group study.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008082
title: Investigation of the effects of repeated oral doses of 500 \xb5g roflumilast on male reproductive parameters in healthy subjects - a double-blind, placebo controlled, randomized, parallel-group study\n

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008083
title: Six weeks treatment with 0.5 mg (500 \xb5g) B9302-107 versus placebo added to 500 \xb5g beclomethasone dipropionate (BDP) in patients with asthma.  A double-blind, randomized parallel group study.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008084
title: Six weeks treatment with 0.5mg B9302-107 versus placebo in patients with asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008085
title: Six weeks treatment with 0.5 mg (500 mg) B9302-107 versus 500 mg beclomethasone dipropionate (BDP) in patients with asthma. A double-blind, double dummy, randomised parallel group study.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008087
title: 40 weeks treatment with 0.5 mg roflumilast in patients with asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008088
title: 12 weeks treatment with 500 mg roflumilast versus 10 mg montelukast in patients with asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008090
title: Safety and efficacy of Roflumilast versus placebo in subjects with bronchial asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008091
title: 12 weeks treatment with 250 \xb5g roflumilast versus placebo in patients with asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008092
title: 12 weeks treatment with 125 \xb5g roflumilast versus 250 \xb5g roflumilast versus placebo in patients with asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008093
title: 26 weeks treatment with 250 \xb5g vs. 500 \xb5g roflumilast vs. placebo in patients with chronic obstructive pulmonary disease (dose range finding trial).

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008096
title: Comparison of safety and efficacy of 250 \xb5g roflumilast versus 500 \xb5g roflumilast versus placebo over 12 weeks in patients with chronic obstructive pulmonary disease (COPD).

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008097
title: Efficacy and safety of roflumilast 500 \xb5g once daily compared with placebo as an add-on therapy to fluticasone propionate 125 \xb5g twice daily over 24 weeks in patients with asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008098
title: A comparison of 500 \xb5g Roflumilast versus 10 mg Montelukast. A 24 weeks double-blind study in patients with Asthma. The PRIME-study.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008099
title: A comparison of treatment with 250 \xb5g roflumilast versus 500 \xb5g roflumilast versus placebo over 24 weeks in patients with chronic obstructive pulmonary disease (COPD).

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008100
title: Effect of 500 \xb5g roflumilast on exercise tolerance and respiratory reserve in patients with chronic obstructive pulmonary disease. A 12 weeks double blind study  with roflumilast once daily versus placebo. The INSPIRE Study\n

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008102
title: Bioequivalence Study of a Metformin XR 1 x 1000-mg Tablet Relative to Metformin XR 2 x 500-mg Tablets in Healthy Subjects in a Fed Condition.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008103
title: Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 1000 mg Metformin Extended Release (XR) Tablet Relative to 5 mg of Saxagliptin Tablet and 1000 mg Metformin XR Tablet Co-administered to Healthy Subjects in a Fed Condition

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008104
title: A Pharmacokinetics/Pharmacodynamics Study of Saxagliptin Following Multiple Dose Administration of 2.5mg Twice-Daily as Compared to 5mg Once-Daily When Administered with Standard Meals to Healthy Subjects.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008105
title: Bioequivalance study of the fixeddose combinationof saxagliptin/metform inXR tablets relative to saxagliptin(Onglyza ) tablets and Australia sourced Diabex XR tablets coadministrated to healthy subjects in the fed state during steady-state administration

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008107
title: Pharmacokinetics and systemic effects after single and repeated dosing of fluticasone propionate from Diskus and budesonide from Turbuhaler in asthmatic patients.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008108
title: Determination of fluticasone propionate, budesonide and its fatty acidesters in lung tissue from lung cancer patients after inhalation.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008112
title: A phase I trial to assess the effect of ICI 182,780 (ZD9238) on the pharmacokinetics of a single oral dose of midazolam in healthy male volunteers.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008113
title: A phase I trial to assess the anti-oestrogen effect of ICI 182,780 (ZD9238) on the female reproductive tract in healthy post-menopausal female volunteers.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008114
title: An open, non-randomised trial to compare the pharmacokinetics of ICI 182,780 (ZD9238) in healthy male, pre-menopausal female and post-menopausal female volunteers.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008115
title: A phase I trial to assess the safety, tolerability and pharmacokinetics of ascending oral doses of ZD1839 in healthy male volunteers.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008116
title: A Randomised, Open, 2-Period Crossover, Phase I Trial to Investigate the Effect of Food on the Bioavailability of the Tablet Formulation of ZD1839 in Healthy Male Volunteers

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008117
title: A Phase I Trial to Assess the Absorption, Metabolism and Excretion of a Single Oral Dose of 50 mg [14C]-ZD1839 in Healthy Male Volunteers.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008118
title: A Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Oral Doses of ZD1839 Given Daily over a 3-day Period to Healthy Male Volunteers

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008120
title: A Randomised, Open-Label, Single-Centre Study to Assess the Bioequivalence of Single Doses of the 250 mg ZD1839 Sales Formulation Tablet and the 250 mg ZD1839 Clinical Studies Formulation Tablet in Healthy Male Volunteers

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008121
title: A Randomised, Open-Label, 2-Way Crossover, Phase I Trial to Assess the Effect of Rifampicin on the Pharmacokinetics of a Single Oral Dose of ZD1839 in Healthy Male Volunteers.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/pr00008122
title: A Randomised, Single-Centre Study to Assess the Absolute Bioavailability of a Single Oral dose of ZD1839 in Healthy Male Volunteers

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.